Acquisitions (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended			0 Months Ended	3 Months Ended	6 Months Ended	0 Months Ended	3 Months Ended		6 Months Ended					0 Months Ended
	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013	Oct. 01, 2012 CNS Therapeutics, Inc.	Mar. 19, 2014 Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.	Mar. 28, 2014 Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.	Mar. 28, 2014 Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.	Oct. 01, 2012 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Mar. 28, 2014 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Mar. 29, 2013 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Mar. 28, 2014 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Mar. 29, 2013 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Mar. 28, 2014 Licensing Agreements Ofirmev Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.	Mar. 28, 2014 Secured Debt Term Loan	Mar. 19, 2014 Secured Debt Term Loan	Mar. 19, 2014 Completed Technology Ofirmev Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Cash paid per Cadence share						$ 14.00
Total consideration						1,300,000,000			95,000,000
Acquisition funding, term loan, face amount																1,300,000,000
Discount rate used, completed technology																	13.00%
Net sales	557,800,000	585,300,000	1,098,000,000	1,089,300,000			5,300,000	5,300,000		7,800,000	6,800,000	15,400,000	13,300,000
(Loss) income from continuing operations before income taxes	(8,600,000)	53,500,000	54,400,000	90,400,000			(9,000,000)	(9,000,000)
Acquisition costs						17,600,000
Interest rate															3.50%
Cash payment, net of cash acquired			1,293,200,000	88,100,000					88,100,000
Cash and cash equivalents						43,200,000			3,600,000
Contingent consideration					6,900,000				6,900,000
Contingent consideration, potential maximum					9,000,000				9,000,000
Future milestone payments														$ 25,000,000